The cost of Revlimid can vary based on several factors ... The manufacturer of a brand-name drug can sell it for up to 20 years. When the brand-name drug’s patent expires, multiple manufacturers ...

Bristol-Myers Squibb's blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 billion in sales last year.

“Mesalamine is a difficult to make product with a limited number of suppliers, and this approval highlights the strength of our R&D capabilities. Additionally, the approval of lenalidomide represents ...

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.